Suppr超能文献

肺移植患者合并严重感染时的异基因造血干细胞移植——病例报告

Allogeneic Hematopoietic Stem Cell Transplantation Despite Severe Infection in a Lung Transplanted Patient-A Case Report.

作者信息

Tozzi Monica, Santoni Adele, Franceschini Marta, Malchiodi Margherita, Bernareggi Irene, Esposito Vangone Beatrice, Zuanelli Brambilla Corrado, Zappone Elisabetta, Lenoci Mariapia, Toraldo Francesca, Del Re Valeria, Pietrini Alice, Marchini Elena, Fossi Antonella, Bennett David, Bargagli Elena, Marotta Giuseppe, Bucalossi Alessandro, Bocchia Monica

机构信息

Cellular Therapy and Blood Establishment Unit, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy.

Hematology Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, 53100 Siena, Italy.

出版信息

Microorganisms. 2025 Mar 21;13(4):703. doi: 10.3390/microorganisms13040703.

Abstract

Solid-organ transplant patients require prolonged immunosuppression, increasing their risk of hematologic disorders. For these conditions, allogeneic hematopoietic stem cell transplantation (HSCT) is a potential treatment, but it carries significant risk of treatment-related mortality due to the high possibility of developing rare infectious complications. We report a case of a 55-years-old male with a history of bilateral lung transplantation for extrinsic allergic alveolitis in 2015, who developed acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) with TP53 mutation seven years later. During induction therapy, he experienced systemic fungal infection caused by and he underwent HSCT conditioning with active intravitreal fungal infection. It is noteworthy that cases of patients undergoing HSCT after a prior lung transplant are exceedingly rare. The medical literature primarily documents cases where HSCT is performed first, followed by lung complications. Cases with the opposite timeline are extremely uncommon, and there is limited data on their outcomes; thus, the patient depicted here may help management and decision making of physicians facing this rare sequence of diseases and treatments.

摘要

实体器官移植患者需要长期免疫抑制,这增加了他们患血液系统疾病的风险。对于这些病症,异基因造血干细胞移植(HSCT)是一种潜在的治疗方法,但由于发生罕见感染并发症的可能性很高,它具有与治疗相关的死亡的重大风险。我们报告了一例55岁男性病例,该患者于2015年因外源性过敏性肺泡炎接受了双侧肺移植,七年后发生了伴有TP53突变的急性髓系白血病/骨髓增生异常综合征(AML/MDS)。在诱导治疗期间,他发生了由 引起的系统性真菌感染,并且在患有活动性玻璃体内真菌感染的情况下接受了HSCT预处理。值得注意的是,先前接受过肺移植后又接受HSCT的患者病例极为罕见。医学文献主要记录的是先进行HSCT,随后出现肺部并发症的病例。时间顺序相反的病例极为罕见,关于其结果的数据有限;因此,此处描述的患者可能有助于面临这种罕见疾病和治疗顺序的医生进行管理和决策。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验